Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seres Therapeutics Inc (NQ: MCRB )

6.010 +0.150 (+2.56%)
Streaming Delayed Price Updated: 9:34 AM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,741
Open 5.990
Bid (Size) 6.010 (2)
Ask (Size) 6.040 (5)
Prev. Close 5.860
Today's Range 5.960 - 6.040
52wk Range 2.500 - 9.490
Shares Outstanding 126,076,391
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Stocks React To February Jobs Report: The Winners And Losers
The markets have offered investors a rollercoaster ride this week, with a flurry of activity and developments that have sent shockwaves through various sectors. 
Via Benzinga
Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire

Performance

YTD
+11.30%
+11.30%
1 Month
+19.96%
+19.96%
3 Month
+5.25%
+5.25%
6 Month
-1.96%
-1.96%
1 Year
-20.29%
-20.29%

More News

Read More
Where Seres Therapeutics Stands With Analysts
Via Benzinga
Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Earnings Preview
Via Benzinga
Recap: Seres Therapeutics Q3 Earnings
Via Benzinga
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
Charter Communications, Braze And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
Via Benzinga
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket
Via Benzinga
Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
Via Benzinga
Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022
From Seres Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics’ ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association
From Seres Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.